PFS Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

PFS Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$70.6K	Hold	158	–	–	0.03%	146
2025 Q4	$71.6K	Hold	158	–	–	0.03%	147
2025 Q3	$61.9K	Hold	158	–	–	0.03%	155
2025 Q2	$70.3K	Hold	158	–	–	0.04%	136
2025 Q1	$76.6K	Hold	158	–	–	0.04%	118
2024 Q4	$63.6K	Hold	158	–	–	0.03%	130
2024 Q3	$73.5K	Hold	158	–	–	0.04%	108
2024 Q2	$74.1K	Hold	158	–	–	0.05%	105
2024 Q1	$66K	Hold	158	–	–	0.04%	106
2023 Q4	$64.3K	Hold	158	–	–	0.04%	111
2023 Q3	$54.9K	Hold	158	–	–	0.05%	96
2023 Q2	$55.6K	Buy	158 +39	+33%	+$13.1K	0.05%	99
2023 Q1	$37.5K	Hold	119	–	–	0.04%	109
2022 Q4	$34.4K	Buy	+119	New	+$36.3K	0.04%	108

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

PFS Partners's VRTX Position: Q1 2026 in Review

PFS Partners held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 158 shares worth $70.6K. The position accounts for 0.03% of the portfolio, ranked #146.

PFS Partners first reported a position in VRTX in Q4 2022 and has held it in 14 quarters since. The position peaked at $76.6K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

PFS Partners held 158 shares of Vertex Pharmaceuticals worth $70.6K as of Q1 2026.
PFS Partners left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.03% of PFS Partners's portfolio in Q1 2026, its #146 holding.
PFS Partners first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
PFS Partners's Vertex Pharmaceuticals position peaked at $76.6K in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on PFS Partners's 13F filing for Q1 2026, filed 9 Apr 2026.